Új-Zéland - angol - Medsafe (Medicines Safety Authority)

eli lilly and company (nz) limited - betazole hydrochloride 50 mg/ml - solution for injection - 50 mg/ml - active: betazole hydrochloride 50 mg/ml

Kanada - angol - Health Canada

teva canada limited - erlotinib (erlotinib hydrochloride) - tablet - 25mg - erlotinib (erlotinib hydrochloride) 25mg - antineoplastic agents

Kanada - angol - Health Canada

teva canada limited - erlotinib (erlotinib hydrochloride) - tablet - 100mg - erlotinib (erlotinib hydrochloride) 100mg - antineoplastic agents

Kanada - angol - Health Canada

teva canada limited - erlotinib (erlotinib hydrochloride) - tablet - 150mg - erlotinib (erlotinib hydrochloride) 150mg - antineoplastic agents

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

bracco pty ltd - gadobenate dimeglumine, quantity: 529 mg/ml - injection, solution - excipient ingredients: water for injections - multihance is a paramagnetic contrast agent for use in diagnostic magnetic resonance imaging (mri) indicated for: for use in adults for the enhancement of magnetic resonance imaging (mri) of the liver and central nervous system (cns) for diagnostic use only. for use in adult patients with suspected or known vascular disease for contrast-enhanced magnetic resonance angiography of the abdominal or peripheral arteries where it improves the diagnostic accuracy for detecting clinically significant steno-occlusive vascular disease.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

global medical solutions australia pty limited - gallium (67ga) citrate, quantity: 74 mbq/ml - injection, solution - excipient ingredients: benzyl alcohol; hydrochloric acid; sodium hydroxide; sodium citrate dihydrate; sodium chloride; water for injections - indications as at 23 december 2003: gallium citrate ga67 injection, u.s.p. may be useful in demonstrating the presence of the following malignancies; hodgkins disease, lymphomas and bronchogenic carcinoma. positive ga67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - pemetrexed disodium heptahydrate, quantity: 151.7 mg - injection, powder for - excipient ingredients: hydrochloric acid; mannitol; water for injections; sodium hydroxide - malignant pleural mesothelioma. alimta, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer. alimta in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - pemetrexed disodium heptahydrate, quantity: 699 mg (equivalent: pemetrexed, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid; water for injections; mannitol - malignant pleural mesothelioma. alimta, in combination with cisplatin, is indicated for the treatment of patients with malignant pleural mesothelioma. non-small cell lung cancer. alimta in combination with cisplatin is indicated for initial treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology. alimta as monotherapy is indicated for the treatment of patients with locally advanced or metastatic non-small-cell lung cancer other than predominantly squamous cell histology after prior platinum-based chemotherapy.

Ausztrália - angol - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 1.09 mg (equivalent: topotecan, qty 1 mg) - injection, concentrated - excipient ingredients: tartaric acid; hydrochloric acid; sodium hydroxide; water for injections - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.